贝伐单抗辅助培美曲塞联合顺铂化疗治疗非小细胞肺癌的临床观察

Clinical Observation on the Bevacizumab Combined with Pemetrexed plus Cisplatin in the Treatment of Non-small Cell Lung Cancer

目的：探讨贝伐单抗辅助培美曲塞联合顺铂化疗治疗非小细胞肺癌的临床应用价值。方法将2007年1月-2008年12月我院收治的240例进展期非小细胞肺癌患者纳入研究，随机分为观察组（给予贝伐单抗＋培美曲塞＋顺铂化疗）和对照组（给予培美曲塞＋顺铂化疗），每组120例，观察和比较两组化疗后的近期疗效、远期疗效以及不良反应的发生情况。结果（1）观察组的客观有效率和疾病控制率均显著高于对照组，差异有统计学意义（P〈0.05）；（2）观察组患者的1年、3年、5年生存率均显著高于对照组，无进展生存时间和总生存时间均明显长于对照组，差异有统计学意义（P〈0.05）；（3）两组患者不良反应的发生率比较，差异无统计学意义（P〉0.05）。结论贝伐单抗辅助培美曲塞联合顺铂化疗方案有助于促进非小细胞肺癌的缓解，延长患者的生存时间，且不增加不良反应，具有积极的临床应用价值。

Objective To study the application value of Bevacizumab combined with Pemetrexed plus Cisplatin in the treat-ment of non-small cell lung cancer（NSCLC）. Methods A total of 240 advanced non-small cell lung cancer patients enrolled between January 2007 and December 2008 were randomly divided into observation group which was given bevacizumab＋pe-metrexed＋cisplatin, and control group which was given pemetrexed＋cisplatin, each group with 120 cases. Then recent and long-term therapeutic effect and adverse reaction were observed and compared. Results （1） The overall remission rate （ORR） and disease control rate （DCR） of the observation group were significantly higher than those of control group, and the differences had statistical significance（P〈0.05）. （2） The 1-year, 3-year and 5-year survival rate of observation group were significantly higher than those of control group. The progression free survival and overall survival time of observation group were significantly longer than those of control group. All the differences had statistical significance （P〈0.05）. （3） The differences of adverse reac-tions incidence rate had no statistical significance between two groups （P〉0.05）. Conclusion Bevacizumab combined with pemetrexed＋cisplatin have positive clinical value, for it contributes to improve the remission and prolong overall survival time, meanwhile it will not increase adverse reaction of NSCLC patients.